Measuring the public-health impact of candidate HIV vaccines as part of the licensing process

Marie Claude Boily, Laith Aburaddad, Kamal Desai, Benoit Masse, Steve Self, Roy Anderson

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The full impact of vaccines against infectious diseases is manifest at both the individual and the community levels. We argue that evaluating the community-level impact of HIV vaccine candidates should be an integral part of the licensing process. We describe a framework for the public-health evaluation of an HIV vaccine, which is based on the interactive use of mathematical models and community randomised clinical trials (C-RCTs) following completion of individual-based clinical trials (I-RCTs). Mathematical models of HIV vaccine can be used to take public-health considerations into account during the licensing process and can also help to select promising vaccine candidates for testing in C-RCTs. We also describe community and individual-based measures useful for defining public-health criteria necessary to guide the licensing process. To move forward, it is crucial to reach a consensus on what should constitute adequate public-health criteria. At the very least, a suitable vaccine would provide some individual benefit to vaccinees and not be detrimental to the population at large. In future I-RCTs and C-RCTs, quantifying each protective vaccine characteristic (eg, reductions in susceptibility or viral load) is important if regulators are to evaluate adequately the potential community-level impact of the vaccine across different settings, populations, and conditions of use.

Original languageEnglish
Pages (from-to)200-207
Number of pages8
JournalThe Lancet Infectious Diseases
Volume8
Issue number3
DOIs
Publication statusPublished - Mar 2008
Externally publishedYes

Fingerprint

AIDS Vaccines
Licensure
Public Health
Vaccines
Randomized Controlled Trials
Theoretical Models
Viral Load
Population
Communicable Diseases
Clinical Trials

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Measuring the public-health impact of candidate HIV vaccines as part of the licensing process. / Boily, Marie Claude; Aburaddad, Laith; Desai, Kamal; Masse, Benoit; Self, Steve; Anderson, Roy.

In: The Lancet Infectious Diseases, Vol. 8, No. 3, 03.2008, p. 200-207.

Research output: Contribution to journalArticle

Boily, Marie Claude ; Aburaddad, Laith ; Desai, Kamal ; Masse, Benoit ; Self, Steve ; Anderson, Roy. / Measuring the public-health impact of candidate HIV vaccines as part of the licensing process. In: The Lancet Infectious Diseases. 2008 ; Vol. 8, No. 3. pp. 200-207.
@article{6b3b3239cc524cecafb2f0244a09c651,
title = "Measuring the public-health impact of candidate HIV vaccines as part of the licensing process",
abstract = "The full impact of vaccines against infectious diseases is manifest at both the individual and the community levels. We argue that evaluating the community-level impact of HIV vaccine candidates should be an integral part of the licensing process. We describe a framework for the public-health evaluation of an HIV vaccine, which is based on the interactive use of mathematical models and community randomised clinical trials (C-RCTs) following completion of individual-based clinical trials (I-RCTs). Mathematical models of HIV vaccine can be used to take public-health considerations into account during the licensing process and can also help to select promising vaccine candidates for testing in C-RCTs. We also describe community and individual-based measures useful for defining public-health criteria necessary to guide the licensing process. To move forward, it is crucial to reach a consensus on what should constitute adequate public-health criteria. At the very least, a suitable vaccine would provide some individual benefit to vaccinees and not be detrimental to the population at large. In future I-RCTs and C-RCTs, quantifying each protective vaccine characteristic (eg, reductions in susceptibility or viral load) is important if regulators are to evaluate adequately the potential community-level impact of the vaccine across different settings, populations, and conditions of use.",
author = "Boily, {Marie Claude} and Laith Aburaddad and Kamal Desai and Benoit Masse and Steve Self and Roy Anderson",
year = "2008",
month = "3",
doi = "10.1016/S1473-3099(07)70292-X",
language = "English",
volume = "8",
pages = "200--207",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "3",

}

TY - JOUR

T1 - Measuring the public-health impact of candidate HIV vaccines as part of the licensing process

AU - Boily, Marie Claude

AU - Aburaddad, Laith

AU - Desai, Kamal

AU - Masse, Benoit

AU - Self, Steve

AU - Anderson, Roy

PY - 2008/3

Y1 - 2008/3

N2 - The full impact of vaccines against infectious diseases is manifest at both the individual and the community levels. We argue that evaluating the community-level impact of HIV vaccine candidates should be an integral part of the licensing process. We describe a framework for the public-health evaluation of an HIV vaccine, which is based on the interactive use of mathematical models and community randomised clinical trials (C-RCTs) following completion of individual-based clinical trials (I-RCTs). Mathematical models of HIV vaccine can be used to take public-health considerations into account during the licensing process and can also help to select promising vaccine candidates for testing in C-RCTs. We also describe community and individual-based measures useful for defining public-health criteria necessary to guide the licensing process. To move forward, it is crucial to reach a consensus on what should constitute adequate public-health criteria. At the very least, a suitable vaccine would provide some individual benefit to vaccinees and not be detrimental to the population at large. In future I-RCTs and C-RCTs, quantifying each protective vaccine characteristic (eg, reductions in susceptibility or viral load) is important if regulators are to evaluate adequately the potential community-level impact of the vaccine across different settings, populations, and conditions of use.

AB - The full impact of vaccines against infectious diseases is manifest at both the individual and the community levels. We argue that evaluating the community-level impact of HIV vaccine candidates should be an integral part of the licensing process. We describe a framework for the public-health evaluation of an HIV vaccine, which is based on the interactive use of mathematical models and community randomised clinical trials (C-RCTs) following completion of individual-based clinical trials (I-RCTs). Mathematical models of HIV vaccine can be used to take public-health considerations into account during the licensing process and can also help to select promising vaccine candidates for testing in C-RCTs. We also describe community and individual-based measures useful for defining public-health criteria necessary to guide the licensing process. To move forward, it is crucial to reach a consensus on what should constitute adequate public-health criteria. At the very least, a suitable vaccine would provide some individual benefit to vaccinees and not be detrimental to the population at large. In future I-RCTs and C-RCTs, quantifying each protective vaccine characteristic (eg, reductions in susceptibility or viral load) is important if regulators are to evaluate adequately the potential community-level impact of the vaccine across different settings, populations, and conditions of use.

UR - http://www.scopus.com/inward/record.url?scp=39049168547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049168547&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(07)70292-X

DO - 10.1016/S1473-3099(07)70292-X

M3 - Article

C2 - 18291341

AN - SCOPUS:39049168547

VL - 8

SP - 200

EP - 207

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 3

ER -